Seeking Participants for a New CMT Clinical Trial (for the US only):
A Chance to Help Advance Treatment! The sponsor of the study is NMD Pharma A/S. If you’re living with Charcot-Marie-Tooth (CMT) disease, specifically CMT1 or CMT2 subtypes, you may be eligible to participate in an exciting new clinical trial.
NMD Pharma, a biotechnology company, has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the SYNAPSE-CMT Phase 2 trial. This trial will evaluate the safety, tolerability, and potential effectiveness of an investigational medication, NMD670, which could improve muscle strength and endurance in individuals with CMT.
What’s the Goal of the Study?
NMD670 may enhance communication between nerves and muscles where transmission is impaired, a common issue for people living with CMT. The hope is that this treatment will improve your strength, endurance, and overall daily functioning. By joining the study, you’ll play a critical role in determining whether this therapy could help others with CMT in the future.
NextGen Precision Health, Missouri
Principal Investigator: W. David Arnold, MD
Contact: Neetha Gali | Email: [email protected] | Phone: (573) 882-3065
National Neuromuscular Research Institute, Texas
Principal Investigator: Yessar Hussain, MD
Contact: Stephanie Gonsoulin, RN, BSN | Email: [email protected] | Phone: (512) 920-0140 x210
Other locations, including those in New York, Boston, Kansas, Ohio, and Washington will be opening soon.
0 Comments